Neuronetics' 21.6% Madryn Stake Faces Sale Restrictions After Its Debt-Funding Offering

Madryn's restrictions extend 30 days beyond the final prospectus, while a separate agreement binds Avinash Amin for 90 days.

Share
Neuronetics' 21.6% Madryn Stake Faces Sale Restrictions After Its Debt-Funding Offering

Madryn Asset Management's funds hold approximately 21.6% of Neuronetics, which makes an office-based brain-stimulation treatment system, and face offering-related restrictions on selling their shares. The investment adviser reported the holding and restrictions in an amended SEC ownership disclosure Monday, following the company's public offering to help repay debt.

A Larger Share Base

The reporting funds collectively hold 20,809,561 shares. Their ownership calculation uses 96,478,311 outstanding shares, including the 18,750,000 shares Neuronetics issued and sold in Thursday's offering.

Neuronetics priced those shares at $1.60 each, targeting approximately $30 million before offering expenses. STIM shares stood at $1.25 at Monday's close, when the company's market value was $134 million.

30 Days For Madryn, 90 For Amin

Madryn signed its sale-restriction agreement on November 9. The agreement begins on that date and runs through the close of business 30 days after the offering's final prospectus, subject to exceptions.

The restrictions cover sales, pledges, lending and other transfers, including securities convertible into common shares. They also bar hedges that pass the financial effects of ownership to someone else, demands to register shares for resale and public announcements of an intention to take those actions.

William Blair, the offering's lead underwriting representative, must give written permission before an otherwise prohibited action. Certain transfers to affiliates are permitted if the recipients accept the same restrictions and other requirements are met.

Avinash Amin signed a separate agreement on November 9 covering the same categories of actions through 90 days after the final prospectus. Madryn and its specified affiliates remain governed by Madryn's agreement.

Debt Relief For The Therapy Business

Neuronetics plans to put part of the proceeds toward its term loan from Perceptive Credit Holdings IV. Its credit-facility amendment requires at least $15 million in prepayment, together with interest, fees and costs.

The company said meeting the amendment's conditions would ease minimum-revenue requirements and is expected to resolve the going-concern risk cited in recent quarterly reports—a warning about its ability to keep operating.

Neuronetics sells its NeuroStar Advanced Therapy System and recurring treatment sessions, mainly to U.S. psychiatrists. The non-invasive treatment stimulates brain areas associated with mood; FDA clearances cover major depressive disorder, adult obsessive-compulsive disorder and anxiety symptoms in adults with depression.

The company also operates 93 Greenbrook treatment centers. Clinics and treatment sessions supply most of its revenue, which totaled $149.2 million in 2025.

The lender amendment will terminate automatically if its conditions are neither met nor waived by November 30.

Sources

More on Neuronetics

All Neuronetics (STIM) coverage →